New triple therapy hopes to tame tough breast cancer

NCT ID NCT06110793

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests if a combination of three drugs (lenvatinib, pembrolizumab, and fulvestrant) is safe and works for people with ER-positive, HER2-negative breast cancer that has spread. About 54 adults whose cancer has not responded to other treatments will take part. The goal is to find the best dose and see if the drugs can shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER POSITIVE/HER2 NEGATIVE METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.